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In spite of its conceptual complexity and the clinical challenges it incurs, insight is 
recognized as a central element in the evaluation process of first episode psychosis 
(FEP) and a key determinant of its treatment. Indeed it has been shown to be 
positively correlated to important prognostic factors such as medication adherence 
(Fenton et al., 1997, Olfson et al., 1999) and functional outcome (Saravanan et al., 
2010). On a clinical level, the variability of results around a possible relationship 
between insight and symptom intensity has been suggested that insight might be 
influenced by a  combination of “trait” and “state” factors (for a complete review of 
insight, refer to (Elowe and Conus, 2017)).  However, while insight can have a 
positive impact on FEP, it may also be associated with increased depression level 
(Misdrahi et al., 2014) and suicidal behavior (Vilaplana et al., 2015), phenomenon 
coined as the “insight paradox” which has been confirmed by a recent meta-analysis 
(Belvederi Murri et al., 2015). More specifically, higher levels of the self-reflection 
component of cognitive insight showed a significant positive correlation with 
depression (Palmer et al., 2015). Several studies have tried to identify factors that 
could moderate this association such as the patients’ beliefs about the illness, 
including the contingency of self-stigma (Lysaker et al., 2007), their coping strategies 
and their struggle for recovery (Belvederi Murri et al., 2015), premorbid adjustment 
(Campos et al., 2011) or deficits in social cognition and metacognition (Lysaker et al., 
2013). Assessment of neurocognitive function and phenomenological reflection have 
also started to attract attention as potential confounding variables of the relationship 
between insight and depression (Belvederi Murri et al., 2015) as well as the concept 
of social identity (Klaas et al., 2017). 
Surprisingly, no study has questioned the role of cannabis use as a potential 
mediator in the link between insight and depression. This is astonishing, considering 
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the high prevalence of its use among early psychosis patients (Zammit et al., 2008) 
and its impact on various aspects of the disorder. Indeed, besides increasing the risk 
to develop psychosis if used in high quantity at an early age (Lambert et al., 2005), 
patients who use cannabis have been found to have a poorer functional outcome 
than patients who do not (Zammit et al., 2008). Moreover, cannabis users seem to be 
more prevalent among FEP patients who are non-adherent to medication compared 
with adherent FEP patients (Coldham et al., 2002). 
Interestingly, a recent meta-analysis has brought strong arguments for an association 
between cannabis use and a higher risk to develop depressive disorders (Lev-Ran et 
al., 2014). While the authors recognize the possible implication of significant 
confounding or common factors, there is no mention of the possible moderating role 
of insight in this association. This issue is of importance considering that if proven 
true, it may provide a new treatment target for the prevention of depression in FEP.  
With this in mind we explored, in a cohort of FEP patients followed-up over 36 
months, if patients with high insight and using more cannabis at the beginning of the 
program would display more depressive symptoms after the first year after entry into 
the program. The first aim of our prospective study was to examine if cannabis use 
moderates the alleged association between baseline insight and depression one year 
later. Because adequate medication could play an important role in depression 
levels, medication adherence was included in the models. 
Our secondary aim was to explore the evolution of that association between 12 and 
36 months after entry into the program, and the potential relationship between 
baseline predictors such as insight, cannabis use and medication adherence, on 
positive and negative symptomatology on the one hand, and functional outcome on 
the other hand. 
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2. Material and methods 
2.1 Subjects 
Data were gathered among recent-onset FEP patients enrolled in a specialized early 
psychosis program named TIPP (Treatment and early Intervention in Psychosis 
Program), designed and launched in 2004 at the Department of Psychiatry in 
Lausanne (CHUV), Switzerland (Baumann et al., 2013). Patients are referred to the 
program by the hospital, general practitioners, social professional networks or 
families, and regardless of their socioeconomic status. Therefore, the study sample is 
representative of the entire population of patients with first-episode psychosis who 
need specialized psychiatric treatment. Inclusion criteria to the program are age 
between 18 and 35, residence in the catchment area around Lausanne (population of 
about 300’000) and meeting criteria for psychosis according to the “Psychosis 
threshold” subscale of the Comprehensive Assessment of At Risk Mental State 
(CAARMS) scale (Yung et al., 2005). Subjects who received antipsychotic medication 
for a total duration of more than six months, or those with mental retardation 
(intelligence quotient below 70), or displaying psychosis secondary to substance use 
or organic brain disorders are referred to other treatment programs. 
The Research and Ethics Committee of the Faculty of Biology and Medicine of 
Lausanne University granted permission to access all clinical data for research 
purposes, and all patients who enter the program do so on a voluntary basis and are 
automatically included in the study if they meet the clinical inclusion criteria. 
After the inclusion, the TIPP program consists of a three-year individual treatment by 
a psychiatrist and a case manager, antipsychotic medication, psychosocial and family 
interventions whenever needed. Cannabis users are not provided with a specific 
intervention apart from psychoeducation about the effects of pursuing cannabis use 
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in the context of psychosis. A questionnaire has been designed to assess 
sociodemographic elements, past medical and psychiatric history, insight into the 
illness, substance use, adherence to medication, exposure to life events, and global 
functioning. At baseline, it is completed by the case managers, and additional 
relevant information is eventually computed during follow-up. Throughout the three-
year program, similar follow-up assessments are made at 2, 6, 12, 18, 24, 30, and 36 
months respectively. Symptomatology is assessed by trained psychologists and 
psychiatrists within the same deadlines. Symptom assessment was conducted by a 
psychologist who was 100% independent of patients’ treatment and had received 
standardized training prior to the study. Inter rater reliability standards for the PANSS  
have been verified throughout the training using video-taped interviews and 
consensus reference ratings. 
2.2 Definitions and assessments 
The diagnostic procedure starts at the first contact with psychiatric care. All clinical 
and diagnostic elements available at the entry of the program are taken into 
consideration and integrated in the diagnostic process that extends throughout the 
program. The consensus diagnostic procedure is realized by a senior psychiatrist and 
the senior psychologist in charge of scale based assessment over the treatment 
period. They both review the entire file once after 18 months and again after 36 
months, or at the end of treatment, and conduct a diagnostic process based on DSM-
IV criteria (American Psychiatric Association, 2000). This final diagnosis was 
considered in the present study. 
Insight was assessed at baseline, 2, 12, 24, and 36 months respectively, by the case 
managers using a Likert type scale (Conus et al., 2007). Thus, insight was 
considered either absent (score 0), partial (score 1), or totally present (score 2). This 
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rating was negatively correlated ( ranging between -.547 and -.414) with the G12 
PANSS item at all follow-up assessments, suggesting adequate convergent validity. 
Information about adherence to medication is collected from the subject and his 
family. Patients taking their medication between 75 and 100 % of the time are 
considered totally adherent to medication. Patients taking their medication between 
25 and 75 % of the time are considered partially adherent to medication. Patients 
taking their medication less than 25 % of the time are considered non adherent to 
medication. 
Symptomatology was assessed by means of a battery of measures at entry into the 
program, at 2, 6, 12, 18, 24, 30, and 36 months after entry into the program. The 
battery includes the Positive and Negative Syndrome Scale (PANSS), the Brief 
Psychiatric Rating Scale (BPRS), the Clinical Global Impression (CGI), the Young 
Mania Rating Scale (YMRS), and the Montgomery-Asberg Depression Rating Scale 
(MADRS). 
Cannabis use was assessed at the same time points with the Case Manager Rating 
Scale (CMRS) (Drake et al., 1990) which grades level of use on a continuum from 
absent - 1 - to extremely severe - 5 -.  
Assessment of global functioning was made with the Social and Occupational 
Functioning Assessment Scale (SOFAS) (Morosini et al., 2000). 
2.3 Statistical analysis 
In order to study whether the relationship between insight and the different outcomes 
could be moderated by medication adherence and substance use, a series of 
multivariate regression models were estimated.  
3. Baseline insight, medication adherence and cannabis use score were entered 
as independent variables while the PANSS positive score, PANSS negative 
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score, the MADRS score and the SOFAS score after one year were alternately 
selected as the dependent variable. Two-way and three way interaction terms 
between insight, medication adherence and cannabis use were also entered 
as predictors. In order to avoid multicollinearity issues, predictors were 
centered before computing the interaction terms. Significance of simple and 
interaction terms allows to study whether predictors of various outcomes have 
additive respectively multiplicative effects. In other words, they answer the 
question whether baseline medication adherence and substance use do in fact 
moderate the relationship between insight and the outcomes. The various 
scores were used in a continuous way to estimate the model parameters. To 
facilitate interpretation, graphs were built with high and low scores 
corresponding to levels one standard deviation over/below the mean. These 
regression models were estimated with IBM SPSS version 23. All statistical 
tests were two-tailed and significance was determined at the .05 level.Results 
3.1 Patient characteristics 
Data stem from the prospective follow-up of the first 214 patients who were enrolled 
in the program and who completed 36 months of assessment.  
The sociodemographic and baseline clinical characteristics of the study sample are 
given in table 1.  
3.2 Moderating role of cannabis use in the insight – depression association 
There was no main effect of insight, medication adherence and cannabis use at the 
beginning of the program on depression measured 12 months later. However, the 
three-way interaction term (cannabis use x insight x medication adherence) was 
significant ( = .405, p = .020) revealing a complex relationship between these three 
variables and depression. The results are depicted in figure 1. High and low levels 
correspond to scores one standard deviation above respectively below the mean. 
While a high level of insight tends to be significantly associated with higher MADRS 
scores in patients with high medication adherence and high cannabis use, 
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depression decreases significantly in patients with high medication adherence and 
low cannabis use when insight is present. Finally, there is almost no effect of insight 
on depression scores with patients with low medication adherence and heavy 
cannabis use. 
3.3 Evolution of the relationship between depression and insight over time 
While the level of depression tends to globally decrease over the three-year program, 
we found no association between any of the independent variables measured at the 
beginning of the program and depression after 24 and 36 months respectively.  
3.4 Positive and negative symptomatology 
Low cannabis use at baseline negatively predicted positive symptomatology after 12 
( = .248, p = .029), and 36 months ( = .272, p = .046) respectively. 
We found a significant three way interaction term (cannabis use x insight x 
medication adherence) ( = .571, p = .001) when predicting positive symptomatology 
after 24 months. The results are depicted in figure 2. In other words, while a high 
baseline level of insight tends to be significantly associated with higher PANSS 
positive scores two years later in patients with high medication adherence and high 
cannabis use, positive symptomatology decreases significantly in patients with high 
medication adherence and low cannabis use when insight is present. 
At the entry into the program, and at 12 and 24 months respectively, insight always 
predicted negative symptomatology after 24 months of follow-up. 
3.5 Global functioning (SOFAS) 
We found that the level of insight always predicted global functioning throughout the 
program. In particular, insight at the beginning of the program was associated with 
higher functioning 12 months later ( = .178, p = .037) and 24 months later ( = .189, 
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p = .045). Other variables like medication adherence and cannabis use were not 
associated with functioning. Finally, the relationship between insight at the beginning 
and functioning 3 years later was not significant anymore ( = .132, p = .174) 
4. Discussion 
While the question of the relationship between depression and insight in psychosis 
has been examined in many respects and is now recognized, the knowledge is still 
limited regarding the possible moderators or confounding factors of this link 
(Belvederi Murri et al., 2015), even more so in the early phase of psychosis. To our 
knowledge, this is the first prospective study conducted with FEP patients exploring 
the potential moderating role of cannabis use in the relationship between insight and 
depression. Such a study is important considering that the identification of 
moderating factors linking insight and depression may become interesting targets for 
treatment in order to mitigate the negative consequences of the development of 
insight.  
The main finding of this study is that, among patients presenting with high insight and 
high medication adherence at the entry into a specialized intervention program, 
heavy cannabis users at baseline have significantly higher levels of depression after 
12 months of treatment compared to low-users. In contrast, we did not observe such 
a correlation between cannabis use and depression level at 12 months neither in 
patients with low level of insight at baseline nor in those with poor adherence to 
medication despite high level of insight. Previous studies have brought arguments 
that the endocannabinoid system is possibly related to mood, through an increase in 
serotoninergic and noradrenergic activity (Bambico and Gobbi, 2008). While 
longitudinal studies on this issue have yielded inconsistent results, most of them have 
concluded that frequent early-onset cannabis use is linked to a higher risk of later 
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depression (Moore et al., 2007). However, confounding or common factors 
(biological, personality, social and environmental) probably coexist in this association, 
explaining the discrepancies described above. 
Taken together, our results give support to the hypothesis that cannabis may be a 
moderator in the emergence of depressive symptoms in FEP patients with high level 
of insight and good adherence to treatment. In other words, among patients with 
good insight and who are adherent to treatment, those using cannabis are at 
increased risk to develop depressive symptoms and may therefore need specific 
attention, considering their increased suicide risk (Coentre et al., 2017). In particular, 
interventions aiming at reduction of cannabis use should be offered to these patients 
such as web-based programs (Rooke et al., 2013), comprehensive family-based 
treatment, counseling and prevention information, or cognitive behavioral therapy 
(CBT)-oriented motivational psychotherapy (Olmos et al., 2018).  
The association between cannabis use and higher level of depressive symptoms in 
this patient subgroup was not present at 24 and 36 months. This finding was 
surprising at first glance and caught our attention. One possible explanation could be 
related to the concept of social identity suggesting that patients with high level of 
insight go through a phase of depression that resolves when they have been able to 
build a new sense of identity, which integrates the episode. Furthermore, this positive 
evolution may also be explained by the intensive and comprehensive nature of the 
integrated treatment proposed to patients in a setting similar to other specialized 
programs that have been shown to foster a reduction of depressive symptoms and 
suicidal behavior over time (Coentre et al., 2017).  
We also found that patients with a high cannabis use (in addition to having high 
baseline level of insight and medication adherence), have significantly higher PANSS 
positive scores two years later, than patients with low cannabis use at baseline (in 
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addition to having a high level of insight and high medication adherence). These 
results are in line with previous findings (Schimmelmann et al., 2012), showing that 
those with baseline cannabis use present with higher illness severity. 
Several limitations of this study should be taken into consideration. First, and as 
discussed earlier, insight is a complex concept that might be affected by many 
variables that we have not taken into consideration such as internalized stigma. 
While some studies have suggested stigma being a potential moderator acting 
between insight and depression (Lysaker et al., 2013), others do not support this 
hypothesis (Grover et al., 2018). Second, insight was assessed using a simple three-
point Likert scale, possibly lacking precision. Others have commented on the 
complexity of the concept of insight, arguing that it comprises many overlapping 
constructs. Nonetheless, other Likert-scale type instruments have shown good 
convergent and discriminant validity and reliability (Gerretsen et al., 2014). Third, 
data regarding evolution of cannabis use over the treatment period was not taken 
into consideration, and such fluctuations may have had an influence on depressive 
symptoms. As described above, the TIPP program does not provide cannabis users 
with a specific intervention apart from psychoeducation about the effects of pursuing 
cannabis use in the context of psychosis. Therefore, cannabis use is a variable that 
has been considered as a continuum and was assessed at the seven time points 
throughout the three-year program. Moreover, while a decline by approximately 50 % 
in cannabis use after first episode psychosis is now recognized at follow-up, it usually 
spreads over a number of years (Myles et al., 2016). Fourth, other factors known to 
be possibly associated with depression in first episode psychosis have not been 
taken into account, such as duration of untreated psychosis (DUP). Since the DUP is 
estimated based on the often inaccurate recall of the patient and his or her family 
informants, we chose to exclude this variable to simplify the analysis. Finally, data on 
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pharmacological therapy, mainly the use of antidepressants in the follow up period 
was not taken into consideration in our analysis and could affect the prevalence of 
depression.  
In conclusion, while substantial work has demonstrated the high prevalence of 
depression and suicidal behaviour in first episode psychosis , the present study 
suggests that cannabis use continuation during the year following a first episode 
psychosis may play a significant role in the development or the maintenance of post-
psychotic depression in patients who present with high level of insight and adherence 
to medication. In the context of early intervention programs, specific attention should 
therefore be paid to this subgroup of patients and specific therapeutic strategies 
should be proposed considering the high risk of suicide in such patients.  
The authors have no conflicts of interest to disclose and have not been paid for this 
article. 
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Table 1. Patients demographic, functional and clinical variables characteristics 
 
 Total N = 214 
Age in year, Mean (SD) 24.2 (4.9) 
 














Diagnostic, % (N) 
Schizophrenia 
Schizophreniform/brief psychotic episode 
Schizoaffective disorder 

























































































































PANSS = Positive and Negative Syndrome Scale. MADRS = Montgomery Asberg Depression Rating Scale. 
GAF = Global Assessment of Functioning Scale. CMRS = Case Manager Rating Scale. Medication adherencea = 




Figure 1. Relationship between Insight, Medication adherence and Cannabis use at 
the beginning of the program and depression one year later. 
 
 
Figure 2. Relationship between Insight, Medication adherence and Cannabis use at 














(1) High Insight, High
Medication adherence
(2) High Insight, Low
Medication adherence
(3) Low Insight, High
Medication adherence























(1) High Insight, High
Medication adherence
(2) High Insight, Low
Medication adherence
(3) Low Insight, High
Medication adherence
(4) Low Insight, Low
Medication adherence
